Relay Therapeutics, Inc.
RLAY
$3.21
-$0.055-1.69%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -337.71M | -345.20M | -322.83M | -329.12M | -341.97M |
| Total Depreciation and Amortization | 5.46M | 5.51M | 5.50M | 5.47M | 5.27M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 68.52M | 66.70M | 65.15M | 72.04M | 68.85M |
| Change in Net Operating Assets | 14.62M | -7.43M | -28.56M | -31.89M | -32.46M |
| Cash from Operations | -249.11M | -280.43M | -280.74M | -283.51M | -300.32M |
| Capital Expenditure | -2.02M | -2.14M | -2.50M | -3.99M | -4.13M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.07M | -8.27M | 189.62M | 196.84M | 261.76M |
| Cash from Investing | -41.08M | -10.40M | 187.12M | 192.85M | 257.63M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 270.15M | 291.27M | 81.84M | 82.38M | 34.75M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 270.15M | 291.27M | 81.84M | 82.38M | 34.75M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -20.04M | 441.00K | -11.78M | -8.28M | -7.93M |